Eltrombopag with rituximab versus eltrombopag alone for ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old and have confirmed primary ITP.
- Your platelet count is under 30 (units) on Day 1 (or within 48 hours before Day 1).
- You either had splenectomy more than 6 months ago and it didn’t work or you relapsed, or you still have your spleen and didn’t respond to previous treatment or relapsed.
- You finished any prior ITP medicines before starting (or your dose is not increasing).
- You have had no significant heart problem or known rhythm problem in the last 3 months, and your ECG QT measure is not too high.
- You have no infection in the last month and your blood tests (clotting, liver/kidney) are not too abnormal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two ways to raise platelets for people with immune thrombocytopenia (ITP) who did not respond well to a short course of the platelet-boosting drug rhTPO. One group gets a higher dose of rhTPO, the other switches to a different oral medication, eltrombopag. The goal is to see which approach works better to increase platelet counts safely.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
This trial tests whether adding ianalumab to eltrombopag helps children with immune thrombocytopenia (ITP) who didn't get better with steroids. It aims to find a new option for kids whose platelet counts are low despite treatment.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.